Established Use With Industry-Leading Partners

Epiontis ID has been used in phase 1 to phase 3 studies by some of the most prominent biopharmaceutical companies around the world.

Use of Epigenetic Cell Counting to Determine the Effect of Ozanimod on Circulating Leukocyte Subtypes in Patients With Relapsing Multiple Sclerosis

Phase 1 Study by Celgene/BMS for Ozanimod, 2019

Effects on CD3, Treg, and TH17 Cell Numbers in Skin Biopsies After 16-Week Mirkizumab Treatment, Evaluated by an Epigenetic Assay

Phase 2 Study by Eli Lilly for Mirikizumab, 2019

Quantifying Circulating Th17 Cells by qPCR: Potential as a Diagnostic Biomarker for Rheumatoid Arthritis

Publication in Rheumatology, 2019

Interim Biomarker Analysis of Etigilimab (OMP-313M32), an Anti-TIGIT Antibody, in Advanced Solid Tumors Supports TIGIT-associated Mechanisms of Action

Selective Induction of Activated Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases

Two Posters on Parallel Use of Flow Cytometry and Epiontis ID in Oncology, Nektar and Oncomed, 2019

Selection of Recent Publications